Heparin, Low-Molecular-Weight

serpin family C member 1 ; Homo sapiens







49 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34955853 Safety and Efficacy of Low Molecular Weight Heparin for Thromboprophylaxis in the Elderly: A Network Meta-Analysis of Randomized Clinical Trials. 2021 2
2 32841498 Impact of exogenous antithrombin on low molecular weight heparin anti-Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort with variable antithrombin levels. 2020 Nov 1
3 30660948 Monitoring of heparins in antithrombin-deficient patients. 2019 Mar 1
4 27898513 Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin, and a covalent antithrombin-heparin complex. 2017 Sep 1
5 28168066 Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature. 2017 1
6 28282887 New Insights in Thrombin Inhibition Structure-Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin. 2017 Mar 8 2
7 28667866 A case that illustrates the challenges of managing pregnant patients with antithrombin deficiency: More questions than answers. 2017 Sep 1
8 26686866 Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. 2016 1
9 24164039 [An assay for anti-factor Xa activity of low molecular weight heparins by high performance liquid size exclusion chromatography]. 2013 Jul 1
10 22905983 Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. 2012 Oct 2
11 23010574 Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge. 2012 Dec 1
12 20229677 Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium. 2010 Jan 1
13 17376263 [Highlighting the potential of heparin in the treatment of sepsis in view of failure of KyberSept and OPTIMIST projects]. 2007 Mar 1
14 17489664 Enoxaparin in acute coronary syndromes. 2007 May 1
15 17600391 Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. 2007 1
16 17966105 [The insufficiency of low molecular weight heparin (LMWH) prophylaxis in patients with hereditary antithrombin (AT) deficiency]. 2007 1
17 15567452 Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. 2005 1
18 15957976 Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes. 2005 Jun 1
19 16004430 Rheological characterization of polysaccharide-poly(ethylene glycol) star copolymer hydrogels. 2005 Jul-Aug 6
20 16344381 Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. 2005 Dec 20 1
21 15116263 Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin. 2004 May 1
22 15168893 Unfractionated heparin and other antithrombin mediated anticoagulants. 2004 Spring 1
23 15210403 Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. 2004 Apr 30 1
24 15339877 New anticoagulants for treatment of venous thromboembolism. 2004 Aug 31 1
25 12871355 The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain. 2003 May 1
26 15199446 Low-molecular-weight heparins for the treatment of acute coronary syndromes. 2003 Nov 1
27 11134031 Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. 2001 Mar 30 2
28 11287128 Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. 2001 Apr 3 2
29 11465877 Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. 2001 1
30 11668417 Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins. 2001 Oct 1
31 11096650 Low Molecular Weight Heparin and Coronary Intervention. 2000 Feb 1
32 11124600 Low molecular weight heparin in hemodialysis patients with a bleeding tendency. 2000 Dec 1
33 9684790 Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. 1998 Jul 3
34 9736420 Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. 1998 Aug 15 2
35 9737475 Rationale for the management of coronary syndromes with low-molecular-weight heparins. 1998 Sep 10 1
36 9748565 Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan. 1998 Sep 8 3
37 9868079 [Effect of monoclonal antibody against human tissue factor pathway inhibitor on plasma coagulation time]. 1997 1
38 8822125 Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? 1996 1
39 7932105 [Evaluation of anticoagulant activity for low molecular-weight heparin by chromogenic substrate. Measurement of factor Xa and thrombin activities]. 1994 Aug 1
40 8152901 A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins. 1994 1
41 8137606 Low-molecular-weight heparins for the treatment of deep-vein thrombosis. 1993 Dec 1
42 8259546 The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate. 1993 Sep 1 2
43 1650391 [Low molecular weight heparins in everyday practice]. 1991 1
44 1664095 Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy. 1991 1
45 2173168 Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. 1990 Aug 1 1
46 2196192 Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations. 1990 Mar-Apr 2
47 2561387 [Low molecular weight heparins]. 1989 1
48 2851191 An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition. 1988 Oct 31 1
49 3196877 The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. 1988 Dec 1